Citations (57)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Guangying Sheng, Mengxing Xue, Qinrong Wang, Lijun Wen, Suning Chen, Xinyou Zhang & Xiaofei Yang. (2019) Occurrence of chromosomal abnormalities in Philadelphia chromosome-negative metaphases in patients with chronic-phase chronic myeloid leukemia undergoing TKI treatments. Leukemia & Lymphoma 60:14, pages 3503-3511.
Read now
Read now
Jie-Gen Jiang, Yin Xu, Zhao Wu, Hongyu Ni & Eric X. Wei. (2018) Acute myeloid leukemia developed in Ph− cells with MLL gene amplification in a patient with chronic myelogenous leukemia. Leukemia & Lymphoma 59:11, pages 2731-2733.
Read now
Read now
Qitian Mu, Yizhi Cheng, Weilai Xu, Yungui Wang, Zhimei Chen & Jie Jin. (2010) Acquired Robertsonian translocation is not always suggestive of poor prognosis: a case of acquired Rob(13;14) in Philadelphia chromosome-negative cells of chronic myelogenous leukemia. Leukemia & Lymphoma 51:11, pages 2141-2143.
Read now
Read now
Ila Tamascar & Jeyanthi Ramanarayanan. (2009) Targeted treatment of chronic myeloid leukemia: role of imatinib. OncoTargets and Therapy 2, pages 63-71.
Read now
Read now
Peter Valent. (2007) Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches. Biologics: Targets and Therapy 1:4, pages 433-448.
Read now
Read now
D. Ostro, K. Cheung, S. Kamel-Reid & J. H. Lipton. (2007) Chromosomal abnormalities in chronic myeloid leukemia: Evidence of a hierarchy in imatinib treated cells. Leukemia & Lymphoma 48:5, pages 1029-1031.
Read now
Read now
Articles from other publishers (51)
Matthieu Decamp, Emilie Klein, Catherine Godon, Valentin Lestringant, Pauline Roynard, Olivier Theisen, Mélanie Jimenez-Pocquet, Catherine Roche-Lestienne, Audrey Bidet & Lauren Veronese. (2023) Cytogenetics in the management of myeloproliferative neoplasms, mastocytosis and myelodysplastic/myeloproliferative neoplasms: Guidelines from the Group Francophone de Cytogénétique Hématologique (GFCH). Current Research in Translational Medicine 71:4, pages 103424.
Crossref
Crossref
Thulasi Raman Ramalingam, J. Subramanian, I. Nagarathinam, C. Chandran, L. Vaidhyanathan & J.M. Easow. (2023) An interesting case of chronic myeloid leukemia with twists and turns. Hematology, Transfusion and Cell Therapy.
Crossref
Crossref
Jinming Song, Lynn Moscinski, Ling Zhang & Hailing Zhang. (2023) Case report: Co-existing chronic myeloid leukemia and chronic myelomonocytic leukemia–A clinically important but challenging scenario. Leukemia Research Reports 20, pages 100378.
Crossref
Crossref
Helong Zhao & Michael W. Deininger. (2020) Declaration of Bcr-Abl1 independence. Leukemia 34:11, pages 2827-2836.
Crossref
Crossref
Jenny Rinke, Andreas Hochhaus & Thomas Ernst. (2020) CML - Not only BCR-ABL1 matters. Best Practice & Research Clinical Haematology 33:3, pages 101194.
Crossref
Crossref
Ali Amin Asnafi, Zeinab Deris Zayeri, Saeid Shahrabi, Kazem Zibara & Tina Vosughi. (2018) Chronic myeloid leukemia with complex karyotypes: Prognosis and therapeutic approaches. Journal of Cellular Physiology 234:5, pages 5798-5806.
Crossref
Crossref
Tomonori Nakazato, Noriyoshi Iriyama, Michihide Tokuhira, Maho Ishikawa, Eriko Sato, Tomoiku Takaku, Kei-Ji Sugimoto, Hiroyuki Fujita, Isao Fujioka, Yuta Kimura, Yoshinobu Aisa, Eisaku Iwanaga, Norio Asou, Masahiro Kizaki, Yoshihiro Hatta, Norio Komatsu & Tatsuya Kawaguchi. (2018) Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors. Medical Oncology 35:7.
Crossref
Crossref
Pedro Aurio Maia Filho, Tarcísio Paulo de Almeida Filho, Caroline de Fátima Aquino Moreina-Nunes, Rommel Rodriguez Burbano, José Alexandre Rodrigues de Lemos, Edivaldo Herculano Correa de Oliveira, Bruno Coêlho Cavalcanti, Jamilly Florêncio Pereira, Maritza Cavalcante Barbosa, Fernando Barroso Duarte, Marilena Facundo de Castro, Acy Telles de Souza Quixadá & Romélia Pinheiro Gonçalves Lemes. (2018) Genotoxicity associated with the use of tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Environmental and Molecular Mutagenesis 59:3, pages 260-262.
Crossref
Crossref
Rüdiger Hehlmann. (2017) Prognostic relevance of CCAs/Ph− in CML settled. Blood 130:19, pages 2046-2047.
Crossref
Crossref
Kinuko MitaniYasunobu Nagata, Ko SasakiKenichi Yoshida, Kenichi Chiba, Hiroko Tanaka, Yuichi Shiraishi, Satoru Miyano, Hideki Makishima, Yukitsugu NakamuraYuka NakamuraMotoshi IchikawaSeishi Ogawa. (2016) Somatic mosaicism in chronic myeloid leukemia in remission. Blood 128:24, pages 2863-2866.
Crossref
Crossref
J S Khorashad, S K Tantravahi, D Yan, C C Mason, Y Qiao, A M Eiring, K Gligorich, T Hein, A D Pomicter, A G Reid, T W Kelley, G T Marth, T O'Hare & M W Deininger. (2016) Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy. Leukemia 30:11, pages 2275-2279.
Crossref
Crossref
N Gunnarsson, M Höglund, L Stenke, S Wållberg-Jonsson, F Sandin, M Björkholm, A Dreimane, M Lambe, B Markevärn, U Olsson-Strömberg, H Wadenvik, J Richter & A Själander. (2016) Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia. Leukemia 30:7, pages 1562-1567.
Crossref
Crossref
Wei Wang, Guilin Tang, Jorge E Cortes, Hui Liu, Di Ai, C Cameron Yin, Shaoying Li, Joseph D Khoury, Carlos Bueso-Ramos, L Jeffrey Medeiros & Shimin Hu. (2015) Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. Journal of Hematology & Oncology 8:1.
Crossref
Crossref
Niklas Gunnarsson, Leif Stenke, Martin Höglund, Fredrik Sandin, Magnus Björkholm, Arta Dreimane, Mats Lambe, Berit Markevärn, Ulla Olsson-Strömberg, Johan Richter, Hans Wadenvik, Jonas Wallvik & Anders Själander. (2015) Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. British Journal of Haematology 169:5, pages 683-688.
Crossref
Crossref
Jolanta Skalska-Sadowska, Danuta Januszkiewicz-Lewandowska, Katarzyna Derwich, Anna Pieczonka, Magdalena Samborska & Jacek Wachowiak. (2015)
Ph-negative isolated myeloid sarcoma with
NPM1
gene mutation in adolescent with Ph-positive chronic myeloid leukemia in remission after treatment with allogeneic bone marrow transplantation and imatinib mesylate
. Pediatric Blood & Cancer 62:6, pages 1070-1071.
Crossref
Crossref
M Schmidt, J Rinke, V Schäfer, S Schnittger, A Kohlmann, E Obstfelder, C Kunert, J Ziermann, N Winkelmann, E Eigendorff, T Haferlach, C Haferlach, A Hochhaus & T Ernst. (2014) Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia 28:12, pages 2292-2299.
Crossref
Crossref
Michał Gniot, Krzysztof Lewandowski, Błażej Ratajczak, Maria Lewandowska, Agata Lehmann-Kopydłowska, Małgorzata Jarmuż-Szymczak & Mieczysław Komarnicki. (2014) Transient presence of clonal chromosomal aberrations in Ph-negative cells in patients with chronic myeloid leukemia remaining in deep molecular response on tyrosine kinase inhibitor treatment. Cancer Genetics 207:10-12, pages 503-510.
Crossref
Crossref
Kirthi R. Kumar, Prasad Koduru, Charles Timmons, Sara Monaghan, MaryEllen Cavalier & Hung S. Luu. (2013) Myelodysplastic syndrome (MDS)-associated cytogenetic abnormalities in pediatric chronic myelogenous leukemia. Pediatric Blood & Cancer 60:11, pages E146-E148.
Crossref
Crossref
Giuseppe Saglio & Carmen FavaGiovanna Rege-Cambrin, Emilia Giugliano & Patrizia Scaravaglio. 2013. The Treatment of Chronic Myeloid Leukemia. The Treatment of Chronic Myeloid Leukemia
20
36
.
Pavan Kumar Bhamidipati, Hagop Kantarjian, Jorge Cortes, A. Megan Cornelison & Elias Jabbour. (2012) Management of imatinib-resistant patients with chronic myeloid leukemia. Therapeutic Advances in Hematology 4:2, pages 103-117.
Crossref
Crossref
Sharon Lockhart, Lisa McDonald, Michael Rytting & Ka Wah Chan. (2012) Clonal cytogenetic abnormalities after tyrosine kinase inhibitor therapy in Ph+ all resolution after decitabine therapy. Pediatric Blood & Cancer 59:3, pages 573-575.
Crossref
Crossref
H.-H. Hsiao, Y.-C. Liu, C.-P. Lee, C.-S. Chang & S.-F. Lin. (2012) Philadelphia-negative chromosomal evolution during treatment for chronic myeloid leukemia. Genetics and Molecular Research 11:1, pages 317-321.
Crossref
Crossref
George Papaioannou, Anastasia Athanasiadou, Georgia Voutiadou, Maria Gaitatzi, Ioannis Batsis, Tasoula Touloumenidou & Achilles Anagnostopoulos. (2011) Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate. Cancer Genetics 204:12, pages 692-693.
Crossref
Crossref
Robert P. Hasserjian. (2011) Chronic myelogenous leukemia in the age of imatinib: assessing response, acceleration, and blast phase. Journal of Hematopathology 4:2, pages 81-92.
Crossref
Crossref
Christine M. Morris. 2011. Cancer Cytogenetics. Cancer Cytogenetics
33
61
.
Mariana Serpa, Sabri S Sanabani, Pedro Enrique Dorliac-Llacer, Monika Conchon, Thales Dalessandro Meneguin Pereira, Luciana Nardinelli, Juliana Lima Costa, Mafalda Megumi Yoshinaga Novaes, Patricia de Barros Ferreira & Israel Bendit. (2010) Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission. BMC Hematology 10:1.
Crossref
Crossref
Yusuke Oji, Yoshihiro Oka, Sumiyuki Nishida, Akihiro Tsuboi, Manabu Kawakami, Toshiaki Shirakata, Kazuko Takahashi, Ayako Murao, Hiroko Nakajima, Miwako Narita, Masuhiro Takahashi, Satoshi Morita, Junichi Sakamoto, Toshio Tanaka, Ichiro Kawase, Naoki Hosen & Haruo Sugiyama. (2010) WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient. European Journal of Haematology 85:4, pages 358-360.
Crossref
Crossref
Allen A. Katouli & Natalia L. Komarova. (2010) Optimizing Combination Therapies with Existing and Future CML Drugs. PLoS ONE 5:8, pages e12300.
Crossref
Crossref
T Bumm, J Deininger, A H Newell, H Lawce, S Olson, M Mauro, B Druker & M Deininger. (2010) Clonal chromosomal abnormalities in CD34+/CD38− hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors. Leukemia 24:8, pages 1525-1528.
Crossref
Crossref
Ronald L. Paquette, John Nicoll, Meenal Chalukya, Lucas Gondek, Monika Jasek, Charles L. Sawyers, Neil P. Shah & Jaroslaw Maciejewski. (2010) Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. Leukemia Research 34:6, pages 708-713.
Crossref
Crossref
Robert P. Hasserjian. 2010. Neoplastic Hematopathology. Neoplastic Hematopathology
193
211
.
Gulsun Erdag, Jeanne M. Meck, Aurelia Meloni-Ehrig, Ludmila Matyakhina, Theresa Donohue, Ramaprasad Srinivasan, Philip Mowrey, JoAnn Kelly, Aleah Smith & Richard Childs. (2009) Long-term persistence of nonpathogenic clonal chromosome abnormalities in donor hematopoietic cells after allogeneic stem cell transplantation. Cancer Genetics and Cytogenetics 190:2, pages 125-130.
Crossref
Crossref
Peter Valent. (2008) Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. British Journal of Haematology 142:3, pages 361-378.
Crossref
Crossref
H. Agis, W.R. Sperr, S. Herndlhofer, H. Semper, H. Pirc-Danoewinata, O.A. Haas, C. Mannhalter, H. Esterbauer, K. Geissler, C. Sillaber, U. Jäger & P. Valent. (2007) Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571). Annals of Oncology 18:11, pages 1834-1841.
Crossref
Crossref
A Quintás-Cardama, H Kantarjian, L V Abruzzo & J Cortes. (2007) Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy. Leukemia 21:11, pages 2394-2396.
Crossref
Crossref
Elias Jabbour, Hagop M. Kantarjian, Lynne V. Abruzzo, Susan O'Brien, Guillermo Garcia-Manero, Srdan Verstovsek, Jianqin Shan, Mary Beth Rios & Jorge Cortes. (2007) Chromosomal abnormalities in Philadelphia chromosome–negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 110:8, pages 2991-2995.
Crossref
Crossref
Michael W. N. Deininger, Jorge Cortes, Ron Paquette, Byung Park, Andreas Hochhaus, Michele Baccarani, Richard Stone, Thomas Fischer, Hagop Kantarjian, Dietger Niederwieser, Carlo Gambacorti-Passerini, Charlene So, Insa Gathmann, John M. Goldman, Douglas Smith, Brian J. Druker & François Guilhot. (2007) The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer 110:7, pages 1509-1519.
Crossref
Crossref
Mar Mallo, Marta Salido, Blanca Espinet, José Cervera, Anna Canellas, Juan Carlos Pajuelo, Carmen Pedro, Lourdes Florensa, Miguel Ángel Sanz & Francesc Solé. (2007) Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission?. Leukemia Research 31:9, pages 1315-1317.
Crossref
Crossref
Bruno C. Medeiros, Kathy Chun, Suzanne Kamel‐Reid & Jeffrey Lipton. (2007) Inv (11)(p15q21) in donor‐derived Ph‐negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stemcell transplantation. American Journal of Hematology 82:8, pages 758-760.
Crossref
Crossref
Elisabetta Abruzzese, Alessandro Gozzetti, Sara Galimberti, Malgorzata Monika Trawinska, Tommaso Caravita, Agostina Siniscalchi, Giulia Cervetti, Alessandro Mauriello, Angela Maria Coletta & Paolo De Fabritiis. (2007) Characterization of Ph‐negative abnormal clones emerging during imatinib therapy. Cancer 109:12, pages 2466-2472.
Crossref
Crossref
Leslie R. Rowe, Arthur R. Brothman, William E. Nibley, Michael R. Gaffney & Zhong Chen. (2007) An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment. Cancer Genetics and Cytogenetics 174:1, pages 54-56.
Crossref
Crossref
Elias Jabbour, Jorge Cortes, Susan O'Brien, Mary Beth Rios, Francis Giles & Hagop Kantarjian. (2007) Management of Patients with Newly Diagnosed Chronic Myeloid Leukemia: Opportunities and Challenges. Clinical Lymphoma and Myeloma 7, pages S51-S57.
Crossref
Crossref
Bruno C. Medeiros, Vera Markovic, Suzanne Kamel-Reid & Jeffrey H. Lipton. (2007) Presence of t(1;14)(p13;p11.2) in Philadelphia chromosome–negative cells in a patient with chronic myeloid leukemia. Cancer Genetics and Cytogenetics 173:1, pages 83-84.
Crossref
Crossref
Mira Farquharson & Pat Shepherd. 2007. Myeloproliferative Disorders. Myeloproliferative Disorders
59
74
.
Junia V. Melo & John M. GoldmanDaniela Cilloni & Giuseppe Saglio. 2007. Myeloproliferative Disorders. Myeloproliferative Disorders
15
35
.
Tariq I Mughal & John M Goldman. 2007. Myeloproliferative Disorders. Myeloproliferative Disorders
201
218
.
Jeffrey A. Zonder & Charles A. Schiffer. (2006) Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate. Current Hematologic Malignancy Reports 1:3, pages 141-151.
Crossref
Crossref
Alfonso Quintás-Cardama & Jorge E. Cortes. (2006) Chronic Myeloid Leukemia: Diagnosis and Treatment. Mayo Clinic Proceedings 81:7, pages 973-988.
Crossref
Crossref
Michael J. Mauro. (2006) Defining and Managing Imatinib Resistance. Hematology 2006:1, pages 219-225.
Crossref
Crossref
Michael J. Mauro. (2006) Defining and Managing Imatinib Resistance. Hematology 2006:1, pages 219-225.
Crossref
Crossref
Richard A. Van Etten & Kevin M. Shannon. (2004) Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 6:6, pages 547-552.
Crossref
Crossref